HomeCompareFRG vs ABBV

FRG vs ABBV: Dividend Comparison 2026

FRG yields 6.69% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FRG wins by $33993.77M in total portfolio value
10 years
FRG
FRG
● Live price
6.69%
Share price
$29.88
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33993.88M
Annual income
$33,045,456,229.60
Full FRG calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — FRG vs ABBV

📍 FRG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRG + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRG
Annual income on $10K today (after 15% tax)
$568.94/yr
After 10yr DRIP, annual income (after tax)
$28,088,637,795.16/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, FRG beats the other by $28,088,616,739.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRG + ABBV for your $10,000?

FRG: 50%ABBV: 50%
100% ABBV50/50100% FRG
Portfolio after 10yr
$16996.99M
Annual income
$16,522,740,500.68/yr
Blended yield
97.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

FRG
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$45.00
+50.6% upside vs current
Range: $45.00 — $45.00
Altman Z
1.6
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRG buys
0
ABBV buys
0
No recent congressional trades found for FRG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRGABBV
Forward yield6.69%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$33993.88M$102.3K
Annual income after 10y$33,045,456,229.60$24,771.77
Total dividends collected$33928.56M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$45.00$256.15

Year-by-year: FRG vs ABBV ($10,000, DRIP)

YearFRG PortfolioFRG Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,039$1,338.69$11,550$430.00+$489.00FRG
2$15,894$3,012.35$13,472$627.96+$2.4KFRG
3$24,440$7,433.58$15,906$926.08+$8.5KFRG
4$47,516$21,365.70$19,071$1,382.55+$28.4KFRG
5$128,486$77,643.94$23,302$2,095.81+$105.2KFRG
6$529,916$392,435.13$29,150$3,237.93+$500.8KFRG
7$3,592,275$3,025,265.23$37,536$5,121.41+$3.55MFRG
8$42,176,707$38,332,972.46$50,079$8,338.38+$42.13MFRG
9$886,372,742$841,243,666.14$69,753$14,065.80+$886.30MFRG
10$33,993,875,064$33,045,456,229.60$102,337$24,771.77+$33993.77MFRG

FRG vs ABBV: Complete Analysis 2026

FRGStock

Franchise Group, Inc. owns and operates franchised and franchisable businesses. It operates through six segments: Vitamin Shoppe, Pet Supplies Plus, Badcock, American Freight, Buddy's, and Sylvan. The Vitamin Shoppe segment operates as an omnichannel specialty retailer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products under the BodyTech, True Athlete, plnt, The Vitamin Shoppe, ProBioCare, Fitfactor Weight Management System, and Vthrive The Vitamin Shoppe brands. The Pet Supplies Plus segment operates as an omnichannel retail chain and franchisor of pet supplies and services that includes premium brands, proprietary private labels, and specialty products, as well as offers grooming, pet wash, and other services. The Badcock segment operates as a specialty retailer of furniture, appliances, bedding, electronics, home office equipment, accessories, and seasonal items in a showroom format; and offers multiple and flexible payment solutions and credit options through its consumer financing services. The American Freight segment operates a retail chain the provides in-store and online access to furniture, mattresses, new and out-of-box home appliances, and home accessories; and serves as a liquidation channel for appliance vendors. The Buddy's segment operates as a specialty retailer of consumer electronic, residential furniture, appliances, and household accessories through rent-to-own agreements. The Sylvan segment establishes and grows as a franchisor of supplemental education for Pre-K-12 students and families in the United States and Canada. The company was formerly known as Liberty Tax, Inc., and changed its name to Franchise Group, Inc. in September 2019. Franchise Group, Inc. was incorporated in 2010 and is headquartered in Delaware, Ohio.

Full FRG Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this FRG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRG vs SCHDFRG vs JEPIFRG vs OFRG vs KOFRG vs MAINFRG vs JNJFRG vs MRKFRG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.